Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Retained Earnings (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Retained Earnings for 7 consecutive years, with $12000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 50.0% to $12000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12000.0 through Dec 2025, up 50.0% year-over-year, with the annual reading at $12000.0 for FY2025, 50.0% up from the prior year.
  • Retained Earnings hit $12000.0 in Q4 2025 for BridgeBio Pharma, up from $2000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $31000.0 in Q4 2023 to a low of -$3.3 billion in Q1 2025.
  • Historically, Retained Earnings has averaged -$827.5 million across 5 years, with a median of -$192500.0 in 2021.
  • Biggest YoY gain for Retained Earnings was 125.0% in 2025; the steepest drop was 163184350.0% in 2025.
  • Year by year, Retained Earnings stood at -$1.4 billion in 2021, then soared by 99.98% to -$328000.0 in 2022, then surged by 109.45% to $31000.0 in 2023, then crashed by 74.19% to $8000.0 in 2024, then skyrocketed by 50.0% to $12000.0 in 2025.
  • Business Quant data shows Retained Earnings for BBIO at $12000.0 in Q4 2025, $2000.0 in Q3 2025, and $1000.0 in Q2 2025.